Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy - Full Text View

Sponsor:	Bayer
Information provided by:	Bayer
ClinicalTrials.gov Identifier:	NCT00461123

Purpose

The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin. In the presence of hemoglobin, its application causes vaporization of the tissue and this effect depends on the concentration of hemoglobin in the respective tissue. Therefore, increase of blood-flow in the tissue (here: prostate gland) should exert better efficacy of the laser application and consequently shortening of the required duration of laser application.

Condition	Intervention	Phase
Prostatic Hypertrophy, Benign	Drug: Levitra (Vardenafil, BAY38-9456) Drug: Placebo	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	A Randomized, Double-blind, Parallel Group Prospective Pilot Study to Assess the Effect of Vardenafil on Clinical Outcome and on Procedure Duration After Green Light Laser-ablation of the Prostate Gland for Therapy of Benign Prostate Hypertrophy (BPH)

Resource links provided by NLM:

MedlinePlus related topics: Eye Wear Methamphetamine

Drug Information available for: Methamphetamine hydrochloride Vardenafil Vardenafil dihydrochloride Amphetamine Methamphetamine

U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:

Baseline-adjusted Least Squared (LS) Means of Peak Urinary Flow (Qmax) at 3 Months After Surgery or Last Observation Carried Forward (LOCF) [ Time Frame: baseline and up to 3 months after surgery ] [ Designated as safety issue: No ]
Baseline (pre-surgery Day -1) adjusted least squares (LS)-means at 3 months after surgery (Day +90, last observation carried forward (LOCF)) in peak urinary flow.

Secondary Outcome Measures:

Baseline-adjusted Least Squared (LS) Means of International Prostate Symptom Score (IPSS) Total Score at 3 Months After Surgery or Last Observation Carried Forward (LOCF) [ Time Frame: baseline and up to 3 months after surgery ] [ Designated as safety issue: No ]
Baseline (pre-surgery Day -1) adjusted LS-means at 3 months after surgery (Day +90, LOCF) in IPSS total score. IPSS is a questionnaire on benign prostate hyperplasia, including seven 6-point items on symptoms and one 7-point item on quality of life. Total score: sum of items 1 through 7; minimum: 0 (best); maximum: 41 (worst).
Baseline-adjusted Least Squared (LS) Means of Post-void Residual (PVR) Volume at 3 Months After Surgery or Last Observation Carried Forward (LOCF) [ Time Frame: baseline and up to 3 months after surgery ] [ Designated as safety issue: No ]
Baseline (pre-surgery Day -1) adjusted LS-means at 3 months after surgery (Day +90, last observation carried forward (LOCF)) in PVR volume. PVR is the amount of urine left in the bladder after a person has passed urine.
Baseline-adjusted Least Squared (LS) Means of the Number of Urinary Incontinence Episodes Per Week at 3 Months After Surgery or Last Observation Carried Forward (LOCF) [ Time Frame: baseline and up to 3 months after surgery ] [ Designated as safety issue: No ]
Baseline (pre-surgery Day -1) adjusted LS-means at 3 months after surgery (Day +90, last observation carried forward (LOCF)) in the number of incontinence episodes. Urinary incontinence is an involuntary excretion (passing) of urine. Urinary incontinence episodes were collected in the patient diary.
Duration of Surgery [ Time Frame: on the day of surgery, without any further allowable time window ] [ Designated as safety issue: No ]
Duration of prostate laser ablation, i.e. Greenlight(TM) laser surgery.

Enrollment:	50
Study Start Date:	March 2007
Study Completion Date:	June 2008
Primary Completion Date:	June 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Vardenafil (Levitra, BAY38-9456) One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.	Drug: Levitra (Vardenafil, BAY38-9456) One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
Placebo Comparator: Placebo One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.	Drug: Placebo One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men with benign prostate hypertrophy requiring surgical treatment
Age up to 80 years
Documented, dated, written Informed Consent
Anesthesiologists agreement with swallowing 1 tablet one hour prior surgery

Exclusion Criteria:

Any unstable medical, psychiatric, or substance abuse disorder
History of previous prostatectomy
Patients suspect of prostate cancer
Hereditary degenerative retinal disorder
History of previous Non-arteric Anterior Ischemic Optic Neuropathy (NAION) episode or unilateral vision impairment
Any cardiovascular condition
History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
Uncontrolled atrial fibrillation/flutter at screening
Severe chronic or acute liver disease
Chronic hematological disease which may lead to priapism
Bleeding disorder
Significant active peptic ulceration
Resting hypotension
History of positive test for Hepatitis B surface antigen or Hepatitis C
Symptomatic postural hypotension within 6 months of Visit 1
Patients who subjectively or in the opinion of the investigator did not tolerate the initial dose of study medication well
Subjects who are taking nitrates or nitric oxide donors
Subjects who are taking androgens or anti-androgens
Subjects who are taking potent inhibitors of cytochrome P4503A4
Subjects who have received any investigational drug within 30 days of Visit 1
Using of alpha-blockers during two days prior to first dosing of study medication and after ablation of prostate
Use of inhibitors of 5-alpha reductase after ablation of prostate
Subjects with serum creatinine clearance <30.0 mL/min
Elevation of Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >3 times the upper limit of normal
Subjects with known hypersensitivity to Vardenafil
Subjects who are illiterate or unable to understand subject diaries
Subjects who would be non-compliant with the study visit schedule

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00461123

Locations

Germany

Heidelberg, Baden-Württemberg / 275, Germany, 69112

Sponsors and Collaborators

Bayer

Investigators

Study Director:

Bayer Study Director

Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA. This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Therapeutic Area Head, Bayer Vital GmbH
ClinicalTrials.gov Identifier:	NCT00461123 History of Changes
Other Study ID Numbers:	12496, EudraCT: 2006-004633-15
Study First Received:	April 16, 2007
Results First Received:	September 29, 2009
Last Updated:	April 29, 2011
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:

Prostatic Hyperplasia
Hypertrophy
Prostatic Diseases
Genital Diseases, Male
Pathological Conditions, Anatomical
Vardenafil
Vasodilator Agents

Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 09, 2012